Table 1 Clinicopathological data of analyzed cases
Number of cases | Total % | Valid % | ||
|---|---|---|---|---|
Age | 40 ≥ | 29 | 24.2 | 24.2 |
40 < | 91 | 75.8 | 75.8 | |
cT | T1 | 19 | 15.8 | 15.8 |
T2 | 73 | 60.8 | 60.8 | |
T3 | 15 | 12.5 | 12.5 | |
T4 | 13 | 10.8 | 10.8 | |
pT | pT0 | 20 | 16.7 | 18.7 |
pT1 | 40 | 33.3 | 37.4 | |
pT2 | 34 | 28.3 | 31.8 | |
pT3 | 9 | 7.5 | 8.4 | |
pT4 | 4 | 3.3 | 3.7 | |
Unknown | 13 | 10.8 | ||
cN | N0 | 46 | 38.3 | 40.4 |
N1 | 55 | 45.8 | 48.3 | |
N2 | 9 | 7.5 | 7.9 | |
N3 | 4 | 3.3 | 3.5 | |
Nx | 6 | 5.0 | ||
pN | pN0 | 51 | 42.5 | 48.1 |
pN1 | 36 | 30 | 33.9 | |
pN2 | 13 | 10.8 | 12.3 | |
pN3 | 6 | 5 | 5.7 | |
Nx | 14 | 11.7 | ||
Grade | 1 | 1 | 0.8 | 0.9 |
2 | 46 | 38.3 | 41.8 | |
3 | 63 | 52.5 | 57.3 | |
Unknown | 10 | 8.3 | ||
ER status | Positive | 80 | 66.7 | 66.7 |
Negative | 40 | 33.3 | 33.3 | |
PgR status | 20% > | 8 | 6.7 | 6.7 |
20% ≤ | 49 | 40.8 | 41.2 | |
Negative | 62 | 51.7 | 52.1 | |
Unknown | 1 | 0.8 | ||
HER2 status | Positive | 41 | 34.2 | 34.2 |
Negative | 79 | 65.8 | 65.8 | |
Histological type | Lobular | 6 | 5.0 | 5.1 |
IBC NOS | 112 | 93.3 | 94.9 | |
Other/Unknown | 2 | 1.7 | ||
Molecular subtype | Luminal A | 15 | 12.5 | 12.5 |
Luminal B/HER2- | 38 | 31.7 | 31.7 | |
Luminal B/HER2+ | 27 | 22.5 | 22.5 | |
HER2+ | 14 | 11.7 | 11.7 | |
Triple-negative | 26 | 21.7 | 21.7 | |
Response | Complete | 23 | 19.2 | 19.2 |
Partial | 73 | 60.8 | 60.8 | |
Non-responder | 24 | 20.0 | 20.0 | |
Antracyclines | Yes | 88 | 73.3 | 73.3 |
No | 32 | 26.7 | 26.7 | |
Taxanes | Yes | 99 | 82.5 | 82.5 |
No | 21 | 17.5 | 17.5 | |
Platinum | Yes | 31 | 25.83 | 25.83 |
No | 89 | 74.16 | 74.16 | |
Trastuzumab | Yes | 12 | 10.0 | 10.0 |
No | 108 | 90.0 | 90.0 |